Pentameric and monomeric CRP structure, calcium and phosphocholine, complement regulation, vascular effects, and the limits of causal inference from hs-CRP. Positive and negative cardiovascular trials.
HDL biogenesis and subfractions, ABCA1/ABCG1/SR-BI, cellular CEC assays, inflammatory modifications and hepatic–intestinal transport. Cohorts and trials distinguish functional measurements from proven clinical benefit.
ADMA release from methylated proteins, DDAH1 and DDAH2 catalytic evidence, AGXT2, arginine transport, and NOS inhibition. Clinical associations, measurement methods, and why a reference interval is not a treatment threshold.
rT3 chemistry, DIO1/2/3, transport, receptors and mitochondria. How NTIS differs from hypothyroidism, why FT3/rT3 cannot diagnose blockade, and the limits of treatment and supplement evidence.
Insulin signaling, clamps, HOMA1/HOMA2, QUICKI, two TyG scales and Matsuda: equations, units, validation and the limits of clinical interpretation.
Apo(a) architecture, KIV-2 variation, mg/dL versus nmol/L, and the OxPL–autotaxin valve pathway. Genetic evidence, emerging drugs, and limitations of the 2026 HORIZON announcement.
ApoB-100 and ApoB-48 biology, LDL composition, discordance, small dense LDL, retention, and clinical evidence. Laboratory limitations, treatment targets, and the boundaries of supplement claims.
Reading CV, TIR, and AGP; sensor chemistry, mitochondria, PARP/GAPDH, Brownlee's four branches, eNOS, and glycocalyx. Clinical findings, meal strategies, and limits of transferring targets between populations.
How to add and edit lab results, check specific markers quickly and export to PDF, plus the genetic passport: what it contains, what the PGx section is for and how genetic data can be erased.